| Pang, Qingsong |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
NCT04866381: An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody |
|
|
| Not yet recruiting | 2 | 87 | RoW | SHR-6390, SHR-6390 + Camrelizumab (SHR-1210), Camrelizumab (SHR-1210) + SHR-1020 | Tianjin Medical University Cancer Institute and Hospital | Esophageal Squamous Cell Carcinoma, Progression to PD-1 Antibody | 04/23 | 04/23 | | |
| Recruiting | 2 | 39 | RoW | QL1706, Radiation, Taxol, Cisplatin | Tianjin Medical University Cancer Institute and Hospital | Esophageal Squamous Cell Carcinoma | 09/24 | 09/25 | | |
NCT04936750: A One-arm, Prospective Study Comparing the Effects of Different Body Composition on the Survival of Patients Undergoing Radical Concurrent Chemoradiotherapy for Esophageal Cancer |
|
|
| Recruiting | N/A | 120 | RoW | Analysis of body composition | Tianjin Medical University Cancer Institute and Hospital | Brief Description of Focus of Study | 03/24 | 12/24 | | |
NCT05828875: A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy |
|
|
| Not yet recruiting | N/A | 1000 | RoW | questionnaire investigation | Tianjin Medical University Cancer Institute and Hospital | Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival | 05/24 | 07/24 | | |
